CriticalClass Ia antiarrhythmic with antimuscarinic activity×Systemic antimycotics. Imidazole derivatives
Updated · Methodology
Mechanism
According to the Spanish disopyramide summary of product characteristics (SmPC), there is evidence that the enzyme CYP3A metabolises disopyramide, so inhibitors of this enzyme, including azole antifungals, can raise disopyramide blood levels (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ketoconazole is a strong CYP3A4 inhibitor, and the EU ketoconazole SmPC lists disopyramide among drugs whose plasma levels ketoconazole can raise, with possible QT prolongation (ketoconazole SmPC, European Medicines Agency, EMA). Strong CYP3A4 inhibitors such as ketoconazole have not been studied clinically with disopyramide, but life-threatening interactions have been reported when disopyramide was given with clarithromycin and erythromycin, which also inhibit CYP3A4 (disopyramide label, US Food and Drug Administration, FDA). Disopyramide is a class Ia antiarrhythmic, and toxic plasma levels cause marked QT prolongation and QRS widening (AEMPS). Ketoconazole itself can prolong the QT interval (ketoconazole FDA label).
Symptoms
The main risk is ventricular arrhythmia. QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while torsade de pointes can cause repeated fainting (disopyramide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At toxic disopyramide levels the ECG shows marked QT prolongation, QRS widening and atrioventricular block. Symptoms of overdose include fainting, low blood pressure or shock, cardiac arrest and breathing problems (disopyramide SmPC, AEMPS, overdose section). Higher disopyramide levels also raise the risk of its atropine-like effects: acute urinary retention in men with an enlarged prostate, paralytic ileus, especially in older people, and raised eye pressure in angle-closure glaucoma (AEMPS). The US ketoconazole label lists feeling faint, lightheaded or dizzy and an irregular or fast heartbeat as possible symptoms of QT prolongation (ketoconazole label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The EU ketoconazole summary of product characteristics (SmPC) lists disopyramide among contraindicated drugs whose plasma levels ketoconazole can raise, with possible QT prolongation. The US labels for ketoconazole tablets name disopyramide in the boxed warning and in the Contraindications section (ketoconazole SmPC, European Medicines Agency, EMA; ketoconazole labels, US Food and Drug Administration, FDA). The interaction table of the US labels says disopyramide must not be given with ketoconazole under any circumstances or for up to one week after ketoconazole is stopped (ketoconazole FDA labels). The Spanish disopyramide SmPC lists azole antifungals, as CYP3A inhibitors, among combinations that are not recommended (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label warns that CYP3A4 inhibitors given with disopyramide may cause a life-threatening interaction (disopyramide label, FDA). No document says how long to wait after stopping disopyramide. Its half-life is 4.4–8.2 hours in healthy people, about 17 hours in severe renal impairment and longer in hepatic impairment and heart failure (disopyramide SmPC, AEMPS). Disopyramide is contraindicated if the QT interval is already prolonged. During treatment, monitor the QT interval and QRS duration and stop disopyramide if they increase by more than 25% (AEMPS). Ketoconazole is contraindicated in documented prolongation of the corrected QT interval (QTc). Record an electrocardiogram (ECG) before treatment, within the first week and then as clinically indicated (EMA). Monitor potassium and correct it if needed, because imbalance can trigger arrhythmia (disopyramide SmPC, AEMPS). The US label says to correct potassium abnormalities before starting disopyramide (disopyramide label, FDA). The contraindication applies to oral ketoconazole, whose tablets are indicated in the European Union for endogenous Cushing's syndrome (EMA). In adults, plasma ketoconazole was undetectable after the cream was applied to the skin or the gel to the scalp, but measurable after the gel was applied to the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Disopiramida (nº registro 52549), sección 4.5 (2025)– AEMPS, CIMA, nº registro 52549 (Dicorynan), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Norpace (disopyramide) prescribing information (2026)– DailyMed setid e2aa1642-d262-4520-bc6a-9fd3ad795677, revisión 08/2026, Contraindications, Precautions – Drug Interactions
- FDA: Ketoconazole tablets (ketoconazole) prescribing information (2025)– FDA, DailyMed setid 6d4be760-c723-4f54-a854-12c61cf91703 (Strides Pharma Science Limited), version 8, revised 12/2025, Boxed Warning, Contraindications, Warnings (incl. QT Prolongation), Precautions: Drug Interactions, Medication Guide
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)